TABLE 89 Summary results for the sensitivity analyses for mixed-treatment comparison (HR, 95% CI) for PFS/TTP comparing chemotherapy vs chemotherapy in population 1: population with squamous disease

Reference treatment vs comparator	Mixed-treatment comparison A (n = 14), HR (95% CI)	Mixed-treatment comparison B (n = 15), HR (95% CI)	Mixed-treatment comparison C (n = 15), HR (95% CI)	Mixed-treatment comparison D (n = 15), HR (95% CI)
GEM + PLAT vs VNB + PLAT[45,54]	1.05 (0.93 to 1.2)	1.06 (0.93 to 1.21)	1.07 (0.93 to 1.22)	1.06 (0.93 to 1.19)
GEM + PLAT vs PAX + PLAT[47,56]	1.08 (0.97 to 1.22)	1.14 (0.99 to 1.3)	1.12 (0.97 to 1.28)	1.12 (0.98 to 1.27)
GEM + PLAT vs DOC + PLAT[47]	1.05 (0.87 to 1.24)	1.05 (0.86 to 1.25)	1.02 (0.84 to 1.23)	1.06 (0.89 to 1.25)
VNB + PLAT vs PAX + PLAT[51]	1.03 (0.88 to 1.21)	1.08 (0.9 to 1.28)	1.05 (0.88 to 1.24)	1.06 (0.9 to 1.25)
VNB + PLAT vs DOC + PLAT[52,53]	0.99 (0.83 to 1.18)	0.99 (0.81 to 1.18)	0.96 (0.79 to 1.15)	1.00 (0.85 to 1.18)
PAX + PLAT vs DOC + PLAT[47]	0.97 (0.78 to 1.17)	0.92 (0.74 to 1.14)	0.92 (0.73 to 1.13)	0.95 (0.77 to 1.16)

A HR >1 favours the reference treatment and a HR <1 favours the comparator treatment.